Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine

被引:61
|
作者
Zollinger, Wendell D. [1 ]
Donets, Mikhail A. [1 ]
Schmiel, Deborah H. [1 ]
Pinto, Valerian B. [1 ]
Labrie, Joseph E., III [1 ]
Moran, Elizabeth E. [1 ]
Brandt, Brenda L. [1 ]
Ionin, Boris [1 ]
Marques, Ryan [1 ]
Wu, Max [1 ]
Chen, Ping [1 ]
Stoddard, Mark B. [1 ]
Keiser, Paul B. [1 ]
机构
[1] WRAIR, Div Bacterial & Rickettsial Dis, Silver Spring, MD 20910 USA
关键词
Neisseria meningitidis; Vaccine; Vesicles; MENINGITIDIS SEROGROUP-B; LIPOPOLYSACCHARIDE CORE OLIGOSACCHARIDES; SYNERGISTIC BACTERICIDAL ACTIVITY; NEISSERIA-MENINGITIDIS; MONOCLONAL-ANTIBODIES; PROTEIN; IMMUNOGENICITY; DISEASE; POLYSACCHARIDE; CANDIDATE;
D O I
10.1016/j.vaccine.2010.05.006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A vaccine based on native outer membrane vesicles (NOMV) that has potential to provide safe, broad based protection against group B strains of Neisseria meningitidis has been developed. Three antigenically diverse group B strains of N. meningitidis were chosen and genetically modified to improve safety and expression of desirable antigens. Safety was enhanced by disabling three genes: synX, IpxL1, and IgtA. The vaccine strains were genetically configured to have three sets of antigens each with potential to induce protective antibodies against a wide range of group B strains. Preliminary immunogenicity studies with combined NOMV from the three strains confirmed the capacity of the vaccine to induce a broad based bactericidal antibody response. Analysis of the bactericidal activity indicated that antibodies to the LOS were responsible for a major portion of the bactericidal activity and that these antibodies may enhance the bactericidal activity of anti-protein antibodies. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5057 / 5067
页数:11
相关论文
共 50 条
  • [21] A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA
    Keiser, Paul B.
    Gibbs, Barnett T.
    Coster, Trinka S.
    Moran, E. Ellen
    Stoddard, Mark B.
    Labrie, Joseph E., III
    Schmiel, Deborah H.
    Pinto, Valerian
    Chen, Ping
    Zollinger, Wendell D.
    VACCINE, 2010, 28 (43) : 6970 - 6976
  • [22] Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic
    Aaberge, IS
    Oster, P
    Helland, OS
    Kristoffersen, AC
    Ypma, E
    Hoiby, EA
    Feiring, B
    Nokleby, H
    CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2005, 12 (05) : 599 - 605
  • [23] A Meningococcal Outer Membrane Vesicle Vaccine with Overexpressed Mutant FHbp Elicits Higher Protective Antibody Responses in Infant Rhesus Macaques than a Licensed Serogroup B Vaccine
    Beernink, Peter T.
    Vianzon, Vianca
    Lewis, Lisa A.
    Moe, Gregory R.
    Granoff, Dan M.
    MBIO, 2019, 10 (03):
  • [24] MENINGOCOCCAL SEROGROUP-B OUTER-MEMBRANE VESICLE VACCINE TRIALS IN NORWAY - IMMUNOGENICITY AND EFFICACY STUDIES
    ROSENQVIST, E
    BJUNE, G
    BRYN, K
    CAUGANT, DA
    CLOSS, O
    FREDRIKSEN, JH
    FROHOLM, LO
    GRONNESBY, JK
    HOIBY, EA
    NOKLEBY, H
    WEDEGE, E
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1992, 36 (04) : 639 - 639
  • [25] Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine
    Vermont, CL
    van Dijken, HH
    Kuipers, AJ
    van Limpt, CJP
    Keijzers, WCM
    van der Ende, A
    de Groot, R
    van Alphen, L
    van den Dobbelsteen, GPJM
    INFECTION AND IMMUNITY, 2003, 71 (04) : 1650 - 1655
  • [26] Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine
    Feiring, Berit
    Fuglesang, Jan
    Oster, Philipp
    Naess, Lisbeth M.
    Helland, Oddveig S.
    Tilman, Sandrine
    Rosenqvist, Einar
    Bergsaker, Marianne A. R.
    Nokleby, Hanne
    Aaberge, Ingeborg S.
    CLINICAL AND VACCINE IMMUNOLOGY, 2006, 13 (07) : 790 - 796
  • [27] Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine
    Martin, SL
    Borrow, R
    van der Ley, P
    Dawson, M
    Fox, AJ
    Cartwright, KAV
    VACCINE, 2000, 18 (23) : 2476 - 2481
  • [28] Effect of aluminium hydroxide and meningococcal serogroup c capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine
    Rosenqvist, E
    Hoiby, EA
    Bjune, G
    Aase, A
    Halstensen, A
    Lehmann, AK
    Holst, J
    Michaelsen, TE
    Nokleby, H
    Froholm, LO
    Closs, O
    MODULATION OF THE IMMUNE RESPONSE TO VACCINE ANTIGENS, 1998, 92 : 323 - 333
  • [29] Antibody studies in mice of outer membrane antigens for use in an improved meningococcal B and C vaccine
    Milagres, LG
    Brandileone, MCC
    Sacchi, CT
    Vieira, VSD
    Zanella, RC
    Frasch, CE
    FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 1996, 13 (01): : 9 - 17
  • [30] Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice
    Saunders, NB
    Shoemaker, DR
    Brandt, BL
    Moran, EE
    Larsen, T
    Zöllinger, WD
    INFECTION AND IMMUNITY, 1999, 67 (01) : 113 - 119